Jazz Pharmaceuticals (JAZZ) Q4 2025 earnings review
Record Q4 Finish Masks an Anemic 2026 Growth Outlook
Jazz Pharmaceuticals delivered its highest-ever revenue quarter, closing Q4 with a 10% YoY surge to $1.2 billion. The beat was driven by an impressive 16% acceleration in Xywav and a sharp turnaround in the oncology portfolio (+16% YoY) fueled by the new Modeyso launch and Zepzelca's first-line expansion. However, management's narrative of 'strong momentum into 2026' violently contradicts their own FY26 guidance. Revenue is guided to $4.25-$4.50 billion—a jarring deceleration to just 2.5% growth at the midpoint. With multi-source Xyrem generics expected to disrupt the market and Epidiolex growth suddenly slowing, Jazz is relying on a normalized SG&A profile (absent 2025's massive litigation payouts) to protect the bottom line.
🐂 Bull Case
The oncology portfolio flipped from a 1% YoY decline in Q2 to 16% YoY growth in Q4. Modeyso generated $37M in its first full quarter, while Zepzelca re-accelerated to 15% growth following its label expansion into 1L maintenance SCLC.
Practice-changing Phase 3 HERIZON-GEA-01 results position zanidatamab to reshape 1L treatment for HER2+ metastatic GEA. An sBLA submission is on track for 1Q26, creating a major new revenue stream by late 2026.
🐻 Bear Case
Multi-source Xyrem generics are slated to enter the market in early 2026. The threat of payer disruption is real, reflected in Xywav's FY26 guidance of 'flat to up mid-single digits' despite exiting Q4 at a blistering 16% growth rate.
While Epidiolex officially achieved blockbuster status ($1.06B) in 2025, Q4 growth abruptly decelerated to just 4% YoY. Prior quarter growth was artificially inflated by reserve releases, masking a sluggish underlying volume trend.
⚖️ Verdict: ⚪
Neutral. The company is executing flawlessly on its current product launches, but the severe deceleration implied in 2026 guidance shows the multi-source generic threat is an unavoidable gravitational pull.
Key Themes
Narrative vs. Reality: The 2026 Growth Stall
Management stated Q4's record performance provides 'strong momentum into 2026.' The data explicitly contradicts this. FY26 revenue guidance is $4.25 to $4.50 billion. Against FY25's $4.267 billion, the low end represents an absolute contraction, and the midpoint represents a meager 2.5% growth rate. This is a severe deceleration from the 10% growth achieved in Q4, signaling that management expects heavy turbulence from payer dynamics and generic competition.
Oxybate Generic Disruption Priced In
After years of warning about impending multi-source Xyrem generics in early 2026, the financial impact has finally arrived in the guidance. Despite Xywav's phenomenal 16% YoY growth in Q4 (adding 500 net patients), management is guiding for Xywav to be 'flat to up mid-single digits' in 2026. This confirms fears that generic Xyrem will force aggressive pricing concessions or trigger restrictive payer actions on the broader sleep franchise.
Modeyso and Zepzelca Resuscitate Oncology
The oncology portfolio reversed its mid-year slump, accelerating to $337 million (+16% YoY) in Q4. Zepzelca sales grew 15% to $90 million, shaking off previous 2L competitive headwinds thanks to its newly approved combination with atezolizumab for 1L maintenance. Furthermore, the August 2025 launch of Modeyso (dordaviprone) contributed a robust $37 million in Q4, validating the Chimerix acquisition strategy.
SG&A Normalization Protects Margins
A quick glance at 2026 guidance suggests a massive operational cost-cutting program, with Non-GAAP SG&A falling from $1.60 billion in 2025 to $1.29 billion (midpoint) in 2026. However, context is vital: 2025 Non-GAAP SG&A included over $300 million in combined litigation settlements (Xyrem antitrust and Avadel). The 2026 guidance is not a draconian cut, but a return to a normalized run-rate following the clearance of major legal overhangs.
Epidiolex Blockbuster Hangover
Epidiolex successfully crossed the $1 billion threshold in 2025, but the underlying volume trend is decelerating. After reporting 20% revenue growth in Q3 (which was inflated by reserve releases), Q4 growth crashed to just 4% ($287M). The product requires significant new catalysts to reignite double-digit growth.
Zanidatamab Advancing Toward Major Expansion
Technological innovation in the pipeline is advancing. Jazz expects to submit an sBLA in 1Q26 under Real Time Oncology Review (RTOR) for zanidatamab in HER2+ 1L gastroesophageal adenocarcinoma (GEA). Backed by the HERIZON-GEA-01 trial and an FDA Breakthrough Therapy designation, this positions the asset to become the HER2-targeted agent of choice, drastically expanding its total addressable market beyond the currently approved, but much smaller, biliary tract cancer indication.
Other KPIs
Stable and highly cash-generative. Despite taking a GAAP net loss of $356M for the year—driven by the $948M non-cash IPR&D charge from the Chimerix acquisition—the core business spins off tremendous cash, funding $750M in debt paydown earlier in the year while finishing with $2.4B in cash and investments.
Non-GAAP Gross Margin compressed slightly from 91.6% in 24Q4 to 90.6% in 25Q4, primarily due to changes in product mix as newly launched and acquired products scale. FY26 guidance projects 90%-91% gross margins, confirming this slightly lower margin profile is the new baseline.
Guidance
Decelerating violently. After printing 5% YoY growth in FY25 (and exiting Q4 at +10%), the midpoint of this range implies just 2.5% YoY growth for FY26. The low end implies a revenue contraction.
Decelerating. A stark contrast to the 12% full-year growth achieved in 2025. This implicitly builds in aggressive payer disruption and gross-to-net pricing pressure from incoming Xyrem generics.
Reversing. Down drastically from $1.60 billion in 2025. This is primarily a base-effect optical illusion, as 2025 included over $300M in non-recurring litigation settlements that were not backed out of the Non-GAAP metric.
Accelerating. While the sleep franchise faces generic headwinds, management expects Epidiolex, Modeyso, Zepzelca, and zanidatamab to collectively generate double-digit expansion, acting as the primary defense mechanism against oxybate revenue erosion.
Key Questions
Xywav Guidance Components
Your FY26 Xywav guidance of 'flat to mid-single digits' implies a sharp drop-off from Q4's 16% exit velocity. How much of this deceleration is driven by assumed gross-to-net price concessions versus expected volume loss to multi-source generics?
Epidiolex Underlying Demand
Epidiolex growth slowed to 4% in Q4. With the reserve releases from Q3 now in the rearview mirror, does this 4% figure accurately reflect the underlying run-rate volume growth moving into 2026?
Zanidatamab Pricing Strategy
With the sBLA submission for zanidatamab in 1L GEA on track for Q1, do you anticipate any payer pushback or necessary price restructuring if the drug transitions from a rare BTC indication to a larger frontline GEA population?